MB
MBIO.US Mustang Bio Inc
- Market cap
- USD 3.20M
- P/E
- -
- P/B
- 0.49x
- ROE
- -60.6%
- Dividend yield
- 8.54%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MBIO.US undervalued?
Graham numberThe Graham number of Mustang Bio Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mustang Bio Inc fundamental analysis
No fundamental analysis for Mustang Bio Inc yet.
Mustang Bio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ rela…
Full company profileMustang Bio Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mustang Bio Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -2.00K | -630K | -1.37M | -1.79M | -2.31M | -3.03M | -2.23M | -823K | -41.0K | - |
| Operating Income | 11.4M | -31.8M | -31.2M | -45.9M | -56.8M | -66.7M | -76.2M | -50.7M | -16.2M | -2.43M | -4.38M |
| EBITDA | -11.5M | -31.3M | -30.0M | -43.3M | -54.3M | -64.0M | -71.1M | -48.1M | -14.9M | -1.88M | -3.99M |
| Net Income | -12.7M | -31.3M | -30.7M | -48.2M | -60.0M | -66.4M | -77.5M | -51.6M | -15.8M | -1.92M | -3.99M |
| EPS | -7.24 | -19 | -17 | -20 | -17 | -11 | -11 | -6.00 | -2.57 | -0.39 | -0.59 |
| Balance Sheet | |||||||||||
| Total Assets | 27.5M | 63.5M | 42.8M | 73.4M | 110M | 125M | 92.4M | 17.7M | 9.31M | 17.6M | 14.7M |
| Total Liabilities | 3.22M | 3.66M | 6.36M | 21.8M | 11.5M | 12.8M | 46.1M | 17.6M | 13.2M | 8.06M | 8.10M |
| Shareholders' Equity | 24.3M | 59.8M | 36.4M | 51.7M | 98.4M | 112M | 46.3M | 123K | -3.87M | 9.53M | 6.59M |
| Cash & Short-term Investments | 27.5M | 61.0M | 34.1M | 61.4M | 97.8M | 110M | 75.7M | 6.23M | 6.84M | 17.3M | 14.3M |
| Total Debt | 320K | - | - | 15.5M | 2.23M | 2.03M | 31.4M | 2.50M | 878K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.13M | -12.9M | -19.2M | -33.6M | -37.3M | -53.7M | -65.1M | -49.5M | -11.4M | -5.26M | -3.80M |
| Capital Expenditure | 424K | 2.80M | 7.95M | 3.70M | 4.41M | 5.37M | 3.08M | 114K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -4.13M | -15.7M | -27.2M | -37.3M | -41.7M | -59.0M | -68.1M | -49.6M | -11.4M | -5.26M | -3.80M |
| Ratios | |||||||||||
| ROE | -52.1% | -52.3% | -84.2% | -93.2% | -61.0% | -59.0% | -167.5% | -41,952.8% | - | -20.2% | -60.6% |
| ROA | -46.0% | -49.3% | -71.7% | -65.6% | -54.6% | -53.0% | -83.9% | -290.8% | -169.2% | -10.9% | -27.2% |
| Debt to Equity | 0.01x | - | - | 0.30x | 0.02x | 0.02x | 0.68x | 20.31x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mustang Bio Inc dividends
- Dividend yield
- 8.54%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 273K | 0.06 | - |
| 2024 | USD 611K | 0.10 | - |
| 2023 | USD 477K | 0.06 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 320K | 0.19 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:50 on Jan 16, 2025.
Who owns Mustang Bio Inc
- Insiders 8.01%
- Institutions 9.49%
- Public & others 82.50%
- Shares outstanding 6.74M
- Free float 6.20M
Top funds holding MBIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 33.9K | 0.45% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 4.18K | 0.06% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 1.08K | 0.01% | 0.00% | Sep 2026 |
| Nomura Healthcare Fund Class I | 160.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding MBIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Kestra Advisory Services, LLC | 197K | 2.60% | +11.90% | Jun 2026 |
| BlackRock Inc | 84.7K | 1.12% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 59.5K | 0.78% | +11.77% | Jun 2026 |
| Geode Capital Management, LLC | 42.2K | 0.56% | -54.48% | Jun 2026 |
| CFO4Life Group, LLC | 33.5K | 0.44% | +63.78% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 32.1K | 0.42% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 25.7K | 0.34% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 14.6K | 0.19% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 14.4K | 0.19% | 0.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 13.7K | 0.18% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 13.7K | 0.18% | 0.00% | Jun 2026 |
| UBS Group AG | 4.16K | 0.05% | +13.56% | Jun 2026 |
| Tower Research Capital LLC | 1.90K | 0.03% | 0.00% | Jun 2026 |
| Barclays PLC | 1.12K | 0.01% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 509.00 | 0.01% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 118.00 | 0.00% | 0.00% | Jun 2026 |
| Cullen/Frost Bankers Inc | 13.00 | 0.00% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 6.00 | 0.00% | 0.00% | Jun 2026 |
| Nbc Securities Inc | 3.00 | 0.00% | 0.00% | Jun 2026 |
| Danske Bank A/S. | 2.00 | 0.00% | 0.00% | Jun 2026 |
Mustang Bio Inc company profile
- Company name
- Mustang Bio Inc
- Ticker
- MBIO.US
- Exchange
- USA Stocks
- Listed since
- Aug 22, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- 95 Sawyer Road, Waltham, MA, United States, 02453
- Phone
- 781 652 4500
- Website
- mustangbio.com
About Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Mustang Bio Inc management
5- Mr. Michael S. Weiss Esq., J.D.Executive Chairman · born 1966
- Dr. Manuel Litchman M.D.President, CEO, Interim CFO & Director · born 1954
- Mr. Peter CarneyController & Interim Chief Accounting Officer · born 1987
- Mr. Greg Furrow M.S.Chief Quality Officer
- Ms. Robyn M. HunterCorporate Secretary · born 1962